JP4937127B2 - 肝細胞成長因子活性化物質のモジュレータ - Google Patents

肝細胞成長因子活性化物質のモジュレータ Download PDF

Info

Publication number
JP4937127B2
JP4937127B2 JP2007535866A JP2007535866A JP4937127B2 JP 4937127 B2 JP4937127 B2 JP 4937127B2 JP 2007535866 A JP2007535866 A JP 2007535866A JP 2007535866 A JP2007535866 A JP 2007535866A JP 4937127 B2 JP4937127 B2 JP 4937127B2
Authority
JP
Japan
Prior art keywords
antibody
seq
hgfa
cdr
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007535866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008515918A (ja
Inventor
キルヒホファー，ダニエル，ケイ．
ウー，ヤン
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2008515918A publication Critical patent/JP2008515918A/ja
Application granted granted Critical
Publication of JP4937127B2 publication Critical patent/JP4937127B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2007535866A 2004-10-04 2005-10-03 肝細胞成長因子活性化物質のモジュレータ Expired - Fee Related JP4937127B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61565704P 2004-10-04 2004-10-04
US60/615,657 2004-10-04
PCT/US2005/036300 WO2006042173A2 (en) 2004-10-04 2005-10-03 Modulators of hepatocyte growth factor activator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011177452A Division JP5554298B2 (ja) 2004-10-04 2011-08-15 肝細胞成長因子活性化物質のモジュレータ

Publications (2)

Publication Number Publication Date
JP2008515918A JP2008515918A (ja) 2008-05-15
JP4937127B2 true JP4937127B2 (ja) 2012-05-23

Family

ID=36148972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007535866A Expired - Fee Related JP4937127B2 (ja) 2004-10-04 2005-10-03 肝細胞成長因子活性化物質のモジュレータ
JP2011177452A Expired - Fee Related JP5554298B2 (ja) 2004-10-04 2011-08-15 肝細胞成長因子活性化物質のモジュレータ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011177452A Expired - Fee Related JP5554298B2 (ja) 2004-10-04 2011-08-15 肝細胞成長因子活性化物質のモジュレータ

Country Status (15)

Country Link
US (4) US20060147451A1 (OSRAM)
EP (1) EP1809673B1 (OSRAM)
JP (2) JP4937127B2 (OSRAM)
KR (1) KR101252306B1 (OSRAM)
CN (1) CN101035810B (OSRAM)
AU (1) AU2005294146B2 (OSRAM)
BR (1) BRPI0515670A (OSRAM)
CA (1) CA2577598C (OSRAM)
ES (1) ES2398528T3 (OSRAM)
IL (1) IL181450A0 (OSRAM)
NO (1) NO20072302L (OSRAM)
NZ (1) NZ553327A (OSRAM)
RU (1) RU2418004C2 (OSRAM)
WO (1) WO2006042173A2 (OSRAM)
ZA (1) ZA200701789B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147451A1 (en) 2004-10-04 2006-07-06 Genentech, Inc. Modulators of hepatocyte growth factor activator
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
DK2056874T3 (da) * 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
CN101652389A (zh) * 2007-02-09 2010-02-17 健泰科生物技术公司 抗robo4抗体及其用途
EP3130607B1 (en) 2008-10-06 2024-04-17 Minerva Biotechnologies Corporation Muc1* antibodies
BR112012009245A2 (pt) * 2009-10-19 2019-09-24 Genentech Inc ''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
US20110206704A1 (en) * 2009-10-19 2011-08-25 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activator
EP2491059B1 (en) 2009-10-22 2015-02-25 F.Hoffmann-La Roche Ag Anti-hepsin antibodies and methods using same
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
WO2016081639A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
WO2016130726A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2023172863A1 (en) * 2022-03-07 2023-09-14 Elixiron Immunotherapeutics (hong Kong) Limited Anti-cd36 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356500A (ja) * 2000-12-05 2002-12-13 Mitsubishi Chemicals Corp 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
CA2102463A1 (en) * 1992-11-05 1994-05-06 Mitsubishi Chemical Corporation Protein and gene encoding said protein
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
US7045602B2 (en) * 2000-12-05 2006-05-16 Mitsubishi Chemical Corporation Specific antibody directed to active hepatocyte growth factor activator and method for using the same
US20060147451A1 (en) 2004-10-04 2006-07-06 Genentech, Inc. Modulators of hepatocyte growth factor activator

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356500A (ja) * 2000-12-05 2002-12-13 Mitsubishi Chemicals Corp 活性型肝細胞増殖因子アクティベーターに対する特異的抗体とその使用法

Also Published As

Publication number Publication date
EP1809673A2 (en) 2007-07-25
KR101252306B1 (ko) 2013-04-08
EP1809673B1 (en) 2012-11-28
IL181450A0 (en) 2007-07-04
US20090047291A1 (en) 2009-02-19
JP2012025752A (ja) 2012-02-09
KR20070102470A (ko) 2007-10-18
US20110098449A1 (en) 2011-04-28
US7825221B2 (en) 2010-11-02
US20130217862A1 (en) 2013-08-22
CA2577598C (en) 2016-09-20
CN101035810A (zh) 2007-09-12
CA2577598A1 (en) 2006-04-20
NO20072302L (no) 2007-06-28
NZ553327A (en) 2010-02-26
HK1105006A1 (en) 2008-02-01
CN101035810B (zh) 2011-04-06
JP2008515918A (ja) 2008-05-15
US8969528B2 (en) 2015-03-03
AU2005294146A1 (en) 2006-04-20
RU2007116806A (ru) 2008-11-10
ES2398528T3 (es) 2013-03-19
JP5554298B2 (ja) 2014-07-23
AU2005294146B2 (en) 2011-09-15
BRPI0515670A (pt) 2008-07-29
WO2006042173A3 (en) 2006-08-17
WO2006042173A2 (en) 2006-04-20
US8399629B2 (en) 2013-03-19
US20060147451A1 (en) 2006-07-06
RU2418004C2 (ru) 2011-05-10
ZA200701789B (en) 2008-11-26

Similar Documents

Publication Publication Date Title
JP5554298B2 (ja) 肝細胞成長因子活性化物質のモジュレータ
JP5623272B2 (ja) 抗ｎｏｔｃｈ１ｎｒｒ抗体とその使用方法
JP5902130B2 (ja) 抗エフリンｂ２抗体とその使用方法
JP5889794B2 (ja) 肝細胞増殖因子アクチベーターの調節
AU2011254032B2 (en) Modulators of Hepatocyte Growth Factor Activator
HK1105006B (en) Modulators of hepatocyte growth factor activator
MX2007003832A (en) Modulators of hepatocyte growth factor activator
HK1178180B (en) Modulators of hepatocyte growth factor activator
HK1099027B (en) Monovalent antibody fragments useful as therapeutics
HK1099027A1 (en) Monovalent antibody fragments useful as therapeutics

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120124

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120221

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150302

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4937127

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees